抗类风湿关节炎药物的金纳米颗粒给药系统的合成与生物学评价

IF 4.5 3区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Drug Delivery Science and Technology Pub Date : 2024-11-12 DOI:10.1016/j.jddst.2024.106402

Jiahui Fan , Xuena Li , Meizi Jin , Cheng Li

{"title":"抗类风湿关节炎药物的金纳米颗粒给药系统的合成与生物学评价","authors":"Jiahui Fan , Xuena Li , Meizi Jin , Cheng Li","doi":"10.1016/j.jddst.2024.106402","DOIUrl":null,"url":null,"abstract":"<div><div>The gold nanoparticle-cysteine-methotrexate (GNPs-Cys-MTX) drug delivery system was developed for the passive targeted therapy of rheumatoid arthritis (RA) to enhance drug delivery efficiency while minimizing toxicity and side effects. The preparation and characterization of the GNPs-Cys-MTX drug delivery system were successfully achieved using Cys as a coupling agent. An IL-1β-induced anti-inflammatory study of rheumatoid arthritis fibroblast synoviocytes (RA-FLSs) demonstrated that GNPs-Cys-MTX exhibited dose-dependent anti-inflammatory effects and effectively inhibited the expression of TNF-α, IL-6, and IL-17. Furthermore, studies involving collagen-induced arthritis rats revealed that GNPs-Cys-MTX demonstrated superior therapeutic efficacy compared to free MTX, even at the same drug dose. In summary, this study demonstrates that the GNPs-Cys-MTX drug delivery system can enhance drug efficacy while reducing toxicity and side effects in the treatment of RA.</div></div>","PeriodicalId":15600,"journal":{"name":"Journal of Drug Delivery Science and Technology","volume":"102 ","pages":"Article 106402"},"PeriodicalIF":4.5000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and biological evaluation of gold nanoparticles drug delivery system for anti-rheumatoid arthritis agents\",\"authors\":\"Jiahui Fan , Xuena Li , Meizi Jin , Cheng Li\",\"doi\":\"10.1016/j.jddst.2024.106402\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The gold nanoparticle-cysteine-methotrexate (GNPs-Cys-MTX) drug delivery system was developed for the passive targeted therapy of rheumatoid arthritis (RA) to enhance drug delivery efficiency while minimizing toxicity and side effects. The preparation and characterization of the GNPs-Cys-MTX drug delivery system were successfully achieved using Cys as a coupling agent. An IL-1β-induced anti-inflammatory study of rheumatoid arthritis fibroblast synoviocytes (RA-FLSs) demonstrated that GNPs-Cys-MTX exhibited dose-dependent anti-inflammatory effects and effectively inhibited the expression of TNF-α, IL-6, and IL-17. Furthermore, studies involving collagen-induced arthritis rats revealed that GNPs-Cys-MTX demonstrated superior therapeutic efficacy compared to free MTX, even at the same drug dose. In summary, this study demonstrates that the GNPs-Cys-MTX drug delivery system can enhance drug efficacy while reducing toxicity and side effects in the treatment of RA.</div></div>\",\"PeriodicalId\":15600,\"journal\":{\"name\":\"Journal of Drug Delivery Science and Technology\",\"volume\":\"102 \",\"pages\":\"Article 106402\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drug Delivery Science and Technology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1773224724010712\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Delivery Science and Technology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1773224724010712","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

该研究开发了金纳米粒子-半胱氨酸-甲氨蝶呤（GNPs-Cys-MTX）给药系统，用于类风湿性关节炎（RA）的被动靶向治疗，以提高给药效率，同时最大限度地减少毒性和副作用。以 Cys 为偶联剂，成功制备并表征了 GNPs-Cys-MTX 药物递送系统。IL-1β 诱导的类风湿性关节炎成纤维滑膜细胞（RA-FLSs）抗炎研究表明，GNPs-Cys-MTX 具有剂量依赖性抗炎作用，能有效抑制 TNF-α、IL-6 和 IL-17 的表达。此外，对胶原蛋白诱导的关节炎大鼠进行的研究表明，即使药物剂量相同，GNPs-Cys-MTX 的疗效也优于游离 MTX。总之，这项研究表明，GNPs-Cys-MTX 给药系统在治疗 RA 时可以提高药物疗效，同时降低毒性和副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Synthesis and biological evaluation of gold nanoparticles drug delivery system for anti-rheumatoid arthritis agents

查看原文本刊更多论文

Synthesis and biological evaluation of gold nanoparticles drug delivery system for anti-rheumatoid arthritis agents

The gold nanoparticle-cysteine-methotrexate (GNPs-Cys-MTX) drug delivery system was developed for the passive targeted therapy of rheumatoid arthritis (RA) to enhance drug delivery efficiency while minimizing toxicity and side effects. The preparation and characterization of the GNPs-Cys-MTX drug delivery system were successfully achieved using Cys as a coupling agent. An IL-1β-induced anti-inflammatory study of rheumatoid arthritis fibroblast synoviocytes (RA-FLSs) demonstrated that GNPs-Cys-MTX exhibited dose-dependent anti-inflammatory effects and effectively inhibited the expression of TNF-α, IL-6, and IL-17. Furthermore, studies involving collagen-induced arthritis rats revealed that GNPs-Cys-MTX demonstrated superior therapeutic efficacy compared to free MTX, even at the same drug dose. In summary, this study demonstrates that the GNPs-Cys-MTX drug delivery system can enhance drug efficacy while reducing toxicity and side effects in the treatment of RA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Drug Delivery Science and Technology 医学-药学

CiteScore

8.00

自引率

8.00%

发文量

879

审稿时长

94 days

期刊介绍： The Journal of Drug Delivery Science and Technology is an international journal devoted to drug delivery and pharmaceutical technology. The journal covers all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines, gene delivery, tissue engineering, etc. Hot topics, related to manufacturing processes and quality control, are also welcomed.